Medical Information

The medication of Ritlecitinib for special populations needs to be personalized according to pregnancy, lactation, reproductive potential, children, and liver and kidney function status. The following items detail the medication precautions for each population.

1. Pregnancy period

(1) Animal studies have shown that rituximab may cause embryotoxicity, and pregnant women should evaluate the benefits and risks of treatment.

(2) Pregnancy status should be confirmed before medication, and effective contraceptive measures should be taken during treatment and after discontinuation of medication.

2. Lactation period

(1) It is not clear whether the medication is secreted through breast milk. It is recommended to suspend breastfeeding for at least one week during the treatment period and after the last administration.

(2) If breastfeeding needs to continue, close monitoring of infant adverse reactions such as increased risk of infection should be conducted.

3. People with reproductive potential

(1) Women: Non hormonal contraceptive methods should be used during treatment and within one month after discontinuation to avoid medication interfering with contraceptive effectiveness.

(2) Men: Barrier contraception should be taken during treatment and one week after discontinuation to prevent medication from being transmitted through semen.

4. Children's medication

(1) The safety of medication for adolescents aged 12 and above is equivalent to that of adults, and the dosage should be adjusted according to body weight.

(2) Insufficient data for children under 12 years old, not recommended for use.

5. Elderly medication

(1) Patients over 65 years old do not need to adjust the dosage, but it is necessary to strengthen the monitoring of adverse reactions.

(2) When merging multiple underlying diseases, it is necessary to evaluate the liver and kidney function status.

6. Liver dysfunction

(1) Patients with mild to moderate liver damage should reduce their dosage by 50%, and severe liver damage should be avoided.

(2) Regular monitoring of ALT/AST should be conducted, and treatment should be interrupted when liver enzyme elevation exceeds 3 times ULN.

7. Renal insufficiency

(1) Patients with mild to moderate kidney damage do not need to adjust the dosage.

(2) Patients with severe kidney damage need to adjust the dosage according to eGFR, and patients with end-stage renal disease should avoid using it.